Vicore Pharma (Sweden) Performance
| VICO Stock | SEK 7.60 0.24 3.06% |
The entity has a beta of -1.69, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Vicore Pharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Vicore Pharma is expected to outperform it. At this point, Vicore Pharma Holding has a negative expected return of -0.77%. Please make sure to validate Vicore Pharma's standard deviation, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if Vicore Pharma Holding performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vicore Pharma Holding has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 248.6 M | |
| Total Cashflows From Investing Activities | -7 M |
Vicore |
Vicore Pharma Relative Risk vs. Return Landscape
If you would invest 1,556 in Vicore Pharma Holding on September 4, 2024 and sell it today you would lose (796.00) from holding Vicore Pharma Holding or give up 51.16% of portfolio value over 90 days. Vicore Pharma Holding is generating negative expected returns and assumes 6.8022% volatility on return distribution over the 90 days horizon. Simply put, 60% of stocks are less volatile than Vicore, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Vicore Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vicore Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vicore Pharma Holding, and traders can use it to determine the average amount a Vicore Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1138
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VICO |
Estimated Market Risk
| 6.8 actual daily | 60 60% of assets are less volatile |
Expected Return
| -0.77 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vicore Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vicore Pharma by adding Vicore Pharma to a well-diversified portfolio.
Vicore Pharma Fundamentals Growth
Vicore Stock prices reflect investors' perceptions of the future prospects and financial health of Vicore Pharma, and Vicore Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vicore Stock performance.
| Return On Equity | -0.99 | |||
| Return On Asset | -0.49 | |||
| Current Valuation | 1.22 B | |||
| Shares Outstanding | 81.85 M | |||
| Price To Earning | 163.82 X | |||
| Price To Book | 8.67 X | |||
| EBITDA | (293.13 M) | |||
| Cash And Equivalents | 215.97 M | |||
| Cash Per Share | 5.10 X | |||
| Total Debt | 320 K | |||
| Book Value Per Share | 2.24 X | |||
| Cash Flow From Operations | (265.17 M) | |||
| Earnings Per Share | (4.76) X | |||
| Total Asset | 451.17 M | |||
About Vicore Pharma Performance
Assessing Vicore Pharma's fundamental ratios provides investors with valuable insights into Vicore Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vicore Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Vicore Pharma Holding AB , through its subsidiaries, operates as a biotech company. Vicore Pharma Holding AB was founded in 2000 and is based in Mlndal, Sweden. Vicore Pharma is traded on Stockholm Stock Exchange in Sweden.Things to note about Vicore Pharma Holding performance evaluation
Checking the ongoing alerts about Vicore Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vicore Pharma Holding help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vicore Pharma generated a negative expected return over the last 90 days | |
| Vicore Pharma has high historical volatility and very poor performance | |
| Vicore Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (296.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vicore Pharma Holding has accumulated about 215.97 M in cash with (265.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.1. | |
| Roughly 16.0% of the company outstanding shares are owned by insiders |
- Analyzing Vicore Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vicore Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Vicore Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vicore Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vicore Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vicore Pharma's stock. These opinions can provide insight into Vicore Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vicore Stock Analysis
When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.